These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25709765)

  • 1. Topical interferon alpha-2b for treatment of noninvasive ocular surface squamous neoplasia with 360° limbal involvement.
    Zarei-Ghanavati S; Alizadeh R; Deng SX
    J Ophthalmic Vis Res; 2014; 9(4):423-6. PubMed ID: 25709765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.
    Kim HJ; Shields CL; Shah SU; Kaliki S; Lally SE
    Ophthalmology; 2012 May; 119(5):938-44. PubMed ID: 22361315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
    Boehm MD; Huang AJ
    Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
    Kusumesh R; Ambastha A; Sinha B; Kumar R
    Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.
    Singh M; Gautam N; Kaur M
    Int Ophthalmol; 2019 Feb; 39(2):295-301. PubMed ID: 29362973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amniotic membrane transplantation with topical interferon alfa-2b after excision of ocular surface squamous neoplasia.
    Xie HT; Zhang YY; Jiang DL; Wu J; Wang JS; Zhang MC
    Int J Ophthalmol; 2018; 11(1):160-162. PubMed ID: 29376005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
    Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
    Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
    Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
    BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
    Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
    Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.
    Kaliki S; Bejjanki KM; Desai A; Mohamed A
    Semin Ophthalmol; 2019; 34(7-8):465-472. PubMed ID: 31370766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in in vivo confocal microscopic findings of ocular surface squamous neoplasia during treatment with topical interferon alfa-2b.
    Zarei-Ghanavati M; Mousavi E; Nabavi A; Latifi G; Mehrjardi HZ; Mohebbi M; Ghassemi H; Mirzaie F; Zare MA
    Ocul Surf; 2018 Apr; 16(2):235-241. PubMed ID: 29306088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
    Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
    Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: Comparative analysis of outcomes based on original tumor configuration.
    Shields CL; Constantinescu AB; Paulose SA; Yaghy A; Dalvin LA; Shields JA; Lally SE
    Indian J Ophthalmol; 2021 Mar; 69(3):563-567. PubMed ID: 33595473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
    Sturges A; Butt AL; Lai JE; Chodosh J
    Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia.
    Sripawadkul W; Reyes-Capo D; Zein M; Wylegala A; Albayyat G; Galor A; Karp CL
    Ocul Surf; 2023 Apr; 28():108-114. PubMed ID: 36592780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.
    Geng W; Wang JS; Shi BJ; Xie HT; Zhang MC
    Ophthalmol Ther; 2022 Aug; 11(4):1563-1576. PubMed ID: 35704159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists.
    Meel R; Dhiman R; Vanathi M; Sen S; Gupta N; Tandon R
    Oman J Ophthalmol; 2021; 14(1):27-32. PubMed ID: 34084031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.
    Galor A; Karp CL; Chhabra S; Barnes S; Alfonso EC
    Br J Ophthalmol; 2010 May; 94(5):551-4. PubMed ID: 19493859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Comparative Study of Topical Interferon α2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia.
    Kusumesh R; Ambastha A; Kumar S; Sinha BP; Imam N
    Cornea; 2017 Mar; 36(3):327-331. PubMed ID: 28079688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Interferon Alpha-2b as Primary Treatment for Ocular Surface Squamous Neoplasia.
    Ghaffari R; Barijani S; Alivand A; Latifi G; Ghassemi H; Zarei-Ghanavati M; Djalilian AR
    J Curr Ophthalmol; 2021; 33(3):260-265. PubMed ID: 34765812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.